Location History:
- Slough, GB (2010 - 2016)
- Basel, CH (2011 - 2016)
Company Filing History:
10 out of 3,222 
5 out of 168 
2 out of 4 
Years Active: 2010-2016
Title: Tracy Bayliss: Innovator in Lipid Kinase Inhibition
Introduction
Tracy Bayliss is a prominent inventor based in Basel, Switzerland, known for her significant contributions to the field of lipid kinase inhibition. With a total of 10 patents to her name, she has made remarkable strides in developing compounds that target critical pathways in cancer treatment.
Latest Patents
Among her latest patents are the "Phosphoinositide 3-kinase inhibitor compounds and methods of use." These compounds, represented by Formulas Ia-d, include stereoisomers, geometric isomers, tautomers, solvates, metabolites, and pharmaceutically acceptable salts. They are designed to modulate the activity of lipid kinases, including PI3K, and are aimed at treating disorders such as cancer mediated by these kinases. The methods disclosed involve using these compounds for in vitro, in situ, and in vivo diagnosis, prevention, or treatment of related disorders in mammalian cells.
Another notable patent is the "Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use." This patent covers benzopyran and benzoxepin compounds of Formulas I and II, which are also useful for inhibiting lipid kinases, including p110 alpha and other isoforms of PI3K. Similar to her previous work, these compounds are intended for the diagnosis, prevention, or treatment of cancer and associated pathological conditions.
Career Highlights
Tracy Bayliss has worked with leading companies in the pharmaceutical industry, including Genentech, Inc. and F. Hoffmann-La Roche AG. Her experience in these organizations has allowed her to develop innovative solutions that address critical health challenges.
Collaborations
Throughout her career, Tracy has collaborated with notable professionals in her field, including Adrian Folkes and Richard A. Goldsmith. These partnerships have contributed to her success and the advancement of her research.
Conclusion
Tracy Bayliss is a trailblazer in the field of lipid kinase inhibition, with a strong portfolio of patents that reflect her innovative spirit and dedication to improving cancer treatment. Her work continues to influence the pharmaceutical landscape and offers hope for future advancements in medical science.